[go: up one dir, main page]

NO20021410L - Forebygging og behandling av blodkoagulasjons-relaterte sykdommer - Google Patents

Forebygging og behandling av blodkoagulasjons-relaterte sykdommer

Info

Publication number
NO20021410L
NO20021410L NO20021410A NO20021410A NO20021410L NO 20021410 L NO20021410 L NO 20021410L NO 20021410 A NO20021410 A NO 20021410A NO 20021410 A NO20021410 A NO 20021410A NO 20021410 L NO20021410 L NO 20021410L
Authority
NO
Norway
Prior art keywords
hypercoagulant
persistent
animal
diseases
state
Prior art date
Application number
NO20021410A
Other languages
English (en)
Other versions
NO20021410D0 (no
Inventor
Hiroyuki Saito
Takehisa Kitazawa
Kazutaka Yoshihashi
Kunihiro Hattori
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20021410D0 publication Critical patent/NO20021410D0/no
Publication of NO20021410L publication Critical patent/NO20021410L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Environmental Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)

Abstract

Det er fremskaffet et dyr med en vedvarende hyperkoagulerende tilstand ved å overføre en celle, for eksempel en tumorcelle, som genet til human vevsfaktor er inkorporert i til et forsøksdyr, slik som en mus, og deretter la nevnte celle vokse og tilføre human vevsfaktor kontinuerlig til nevnte forsøksdyr. Denne dyremodellen er egnet for forskning og utvikling av terapeutiske agenser for sykdommer som har en vedvarende hyperkoagulerende tilstand. Den foreliggende oppfinnelsen tilveiebringer også forebyggende eller terapeutiske agenser for sykdommer som har en vedvarende hyperkoagulerende tilstand, en hyperkoagulerende tilstand som skyldes infeksjoner, venøs trombose, arteriell trombose og sykdommer som er et resultat av hypertrofien av vaskulære vev, der nevnte agens innbefatter et antistoff mot human vevsfaktor (human TF) som en aktiv bestanddel.
NO20021410A 1999-10-01 2002-03-21 Forebygging og behandling av blodkoagulasjons-relaterte sykdommer NO20021410L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP28212099 1999-10-01
JP28218899 1999-10-01
JP28184399 1999-10-01
JP28216799 1999-10-01
JP28213499 1999-10-01
JP28219299 1999-10-01
PCT/JP2000/006802 WO2001024626A1 (en) 1999-10-01 2000-09-29 Prevention and treatment of diseases associated with blood coagulation

Publications (2)

Publication Number Publication Date
NO20021410D0 NO20021410D0 (no) 2002-03-21
NO20021410L true NO20021410L (no) 2002-05-24

Family

ID=27554423

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021410A NO20021410L (no) 1999-10-01 2002-03-21 Forebygging og behandling av blodkoagulasjons-relaterte sykdommer

Country Status (18)

Country Link
US (2) US8062638B1 (no)
EP (2) EP2351483A1 (no)
JP (1) JP3859512B2 (no)
KR (1) KR20030008205A (no)
AT (1) ATE498305T1 (no)
AU (1) AU7450600A (no)
BR (1) BR0014667A (no)
CA (1) CA2388408A1 (no)
CZ (1) CZ20021035A3 (no)
DE (1) DE60045638D1 (no)
DK (1) DK1222854T3 (no)
HU (1) HUP0203486A2 (no)
IL (1) IL148980A0 (no)
MX (1) MXPA02003278A (no)
NO (1) NO20021410L (no)
PL (1) PL354961A1 (no)
SK (1) SK4442002A3 (no)
WO (1) WO2001024626A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
EP1374896A4 (en) * 2001-03-26 2005-04-06 Koji Suzuki MEANS TO IMPROVE THE FLUID CHARACTERISTICS OF BLOOD
ATE488135T1 (de) * 2001-05-18 2010-12-15 Chugai Pharmaceutical Co Ltd Menschlichen gewebefaktor produzierendes nichtmenschliches knock-in -tier
MXPA04003051A (es) * 2001-10-02 2004-07-05 Novo Nordisk As Anticuerpos de factor tisular humano.
EP1550455A1 (en) * 2002-05-23 2005-07-06 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
CA2517310C (en) * 2003-02-28 2015-11-24 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations comprising a poloxamer
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
WO1988009817A1 (en) 1987-06-12 1988-12-15 Mount Sinai School Of Medicine Of The City Univers Cloning and expression of human tissue factor
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5879677A (en) * 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP3865418B2 (ja) 1994-07-13 2007-01-10 中外製薬株式会社 ヒトインターロイキン−８に対する再構成ヒト抗体
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
WO1998013388A1 (en) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
EP2363484A3 (en) * 1998-04-03 2012-04-25 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors

Also Published As

Publication number Publication date
US20120073002A1 (en) 2012-03-22
NO20021410D0 (no) 2002-03-21
KR20030008205A (ko) 2003-01-24
EP1222854B1 (en) 2011-02-16
WO2001024626A1 (en) 2001-04-12
JP3859512B2 (ja) 2006-12-20
ATE498305T1 (de) 2011-03-15
US8062638B1 (en) 2011-11-22
PL354961A1 (en) 2004-03-22
DK1222854T3 (da) 2011-03-14
SK4442002A3 (en) 2003-04-01
EP1222854A1 (en) 2002-07-17
DE60045638D1 (de) 2011-03-31
CZ20021035A3 (cs) 2002-08-14
EP2351483A1 (en) 2011-08-03
EP1222854A4 (en) 2006-07-05
IL148980A0 (en) 2002-11-10
MXPA02003278A (es) 2002-09-02
CA2388408A1 (en) 2001-04-12
HUP0203486A2 (hu) 2003-02-28
AU7450600A (en) 2001-05-10
BR0014667A (pt) 2002-07-02

Similar Documents

Publication Publication Date Title
Baron et al. Optimal support of wound healing: new insights
Jackson et al. Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing
Schuppan et al. Hepatic fibrosis: from bench to bedside
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
MEP10508A (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
Cho et al. Diabetic wound healing in a MMP9‐/‐mouse model
Woo et al. Homocysteine stimulates MAP kinase in bovine aortic smooth muscle cells
JP2014139255A (ja) 慢性虚血における亜硝酸塩の使用
NO20021410L (no) Forebygging og behandling av blodkoagulasjons-relaterte sykdommer
Tilkorn et al. The in vitro preconditioning of myoblasts to enhance subsequent survival in an in vivo tissue engineering chamber model
Giri et al. Therapeutic potential of endogenous stem cells and cellular factors for scar-free skin regeneration
DE60325261D1 (de) Behandlungsmethoden während eingriffen in das gefässsystem
US20140242194A1 (en) Use of nitrite salts in treating tissue damage
Skerrett " Matrix algebra" heals life's wounds: recent work shows that interactions between growth factors and the extracellular matrix are of central importance in the process that brings wounds to a close
Steinmetz et al. Atorvastatin-induced increase in progenitor cell levels is rather caused by enhanced receptor activator of NF-kappaB ligand (RANKL) cell proliferation than by bone marrow mobilization
Lai et al. The establishment and evaluation of a swine model of deinagkistrodon acutus snakebite envenomation
EA014296B1 (ru) Средство, активирующее стволовые клетки и/или клетки-предшественники
Silver et al. Heparinase III limits rat arterial smooth muscle cell proliferation in vitro and in vivo
Zhao et al. Heparin reduces overcirculation-induced pulmonary artery remodeling through p38 MAPK in piglet
Perrée et al. Function and structure of pressurized and perfused porcine carotid arteries: effects of in vitro balloon angioplasty
Yamakawa et al. Improved cardioprotection using a novel stepwise ischemic preconditioning protocol in rabbit heart
CA3194392A1 (en) Device and method for applying photobiomodulation
WO2017066605A1 (en) Sequential application of macrophages for wound healing
Ondrick et al. Angiogenesis
Góralczyk et al. Effect of low level laser irradiation on VEGF gene expression in cultured endothelial cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application